Payment overview · 2025
General Payments
$1,390.93
111 reported records · 19 companies
Healthcare provider profile · identity verified
Indumathi Baskar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JEFFERSON CITY, MO · NPI 1083634331
Verified facts
What the public records show
CMS Open Payments records show Indumathi Baskar, M.D. received $1,390.93 in general payments during 2025 across 111 reported records.
Novo Nordisk Inc accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Eliquis, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $220.40 | 15.8% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $214.58 | 15.4% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $190.60 | 13.7% | 16 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $183.80 | 13.2% | 24 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $136.51 | 9.8% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.58 | 5.2% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $57.62 | 4.1% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $48.48 | 3.5% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.20 | 3.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.88 | 2.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.79 | 2.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$26.35 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.73 | 1.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.39 | 1.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.69 | 1.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.37 | 1.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.05 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.16 | 1.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.75 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,390.93 | 111 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $196.41 | 12 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $183.80 | 24 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $162.26 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $144.84 | 14 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $136.51 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $110.69 | 12 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $102.91 | 9 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $72.58 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $72.58 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.65 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $57.62 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $48.48 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.81 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $45.20 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $34.15 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.88 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.79 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.79 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $26.35 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.17 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 39 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 75 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 47 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 103 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 218 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 158 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
110 | 31 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
39 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
218 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
75 | 75 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
218 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
158 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
39 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 14 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
103 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 905 | 200 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 741 | 182 |
| Hydrochlorothiazide | Hydrochlorothiazide | 619 | 165 |
| Atorvastatin Calcium | Atorvastatin Calcium | 601 | 153 |
| Gabapentin | Gabapentin | 583 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 581 | 133 |
| Lisinopril | Lisinopril | 536 | 131 |
| Montelukast Sodium | Montelukast Sodium | 471 | 117 |
| Losartan Potassium | Losartan Potassium | 465 | 111 |
| Pravastatin Sodium | Pravastatin Sodium | 433 | 113 |
| Omeprazole | Omeprazole | 431 | 115 |
| Metformin Hcl | Metformin Hcl | 370 | 97 |
| Sertraline Hcl | Sertraline Hcl | 366 | 73 |
| Alprazolam | Alprazolam | 312 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 293 | 82 |
| Furosemide | Furosemide | 290 | 71 |
| Celecoxib | Celecoxib | 258 | 77 |
| Simvastatin | Simvastatin | 247 | 62 |
| Citalopram Hbr | Citalopram Hydrobromide | 240 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 240 | 43 |
| Potassium Chloride | Potassium Chloride | 237 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 230 | 51 |
| Jardiance | Empagliflozin | 218 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 196 | 57 |
| Atenolol | Atenolol | 178 | 45 |
| Carvedilol | Carvedilol | 170 | 40 |
| Alendronate Sodium | Alendronate Sodium | 164 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 164 | 39 |
| Allopurinol | Allopurinol | 161 | 41 |
| Mounjaro | Tirzepatide | 158 | 23 |
| Venlafaxine Hcl | Venlafaxine Hcl | 154 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 35 |
| Glimepiride | Glimepiride | 152 | 35 |
| Famotidine | Famotidine | 140 | 37 |
| Meloxicam | Meloxicam | 136 | 39 |
| Lovastatin | Lovastatin | 132 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 126 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 25 |
| Trazodone Hcl | Trazodone Hcl | 120 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 118 | 20 |
| Metformin Hcl Er | Metformin Hcl | 118 | 36 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 112 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 48 |
| Synthroid | Levothyroxine Sodium | 110 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 40 |
| Gemtesa | Vibegron | 103 | 19 |
| Bupropion Hcl | Bupropion Hcl | 101 | 18 |
| Ozempic | Semaglutide | 95 | 15 |
| Azithromycin | Azithromycin | 94 | 85 |
| Methylprednisolone | Methylprednisolone | 94 | 83 |
| Mirtazapine | Mirtazapine | 93 | 14 |
| Buspirone Hcl | Buspirone Hcl | 92 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 22 |
| Januvia | Sitagliptin Phosphate | 80 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 20 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 75 | 75 |
| Valacyclovir | Valacyclovir Hcl | 73 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 72 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 52 |
| Ezetimibe | Ezetimibe | 60 | 15 |
| Baclofen | Baclofen | 58 | 32 |
| Donepezil Hcl | Donepezil Hcl | 55 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 17 |
| Cephalexin | Cephalexin | 53 | 47 |
| Clonazepam | Clonazepam | 52 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 30 |
| Fenofibrate | Fenofibrate | 51 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 12 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Eliquis | Apixaban | 47 | 11 |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Valsartan | Valsartan | 45 | 13 |
| Linzess | Linaclotide | 44 | suppressed |
| Klor-Con M20 | Potassium Chloride | 41 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 39 | 39 |
| Benazepril Hcl | Benazepril Hcl | 39 | 11 |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Prolia | Denosumab | 39 | 22 |
| Propranolol Hcl | Propranolol Hcl | 38 | 11 |
| Amoxicillin | Amoxicillin | 37 | 34 |
| Diazepam | Diazepam | 37 | suppressed |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 37 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Np Thyroid | Thyroid,pork | 36 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 30 |
| Kerendia | Finerenone | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 24 |
| Estradiol | Estradiol | 29 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Ciclopirox | Ciclopirox | 22 | 11 |
| Repatha Syringe | Evolocumab | 22 | suppressed |
| Armour Thyroid | Thyroid,pork | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Mirabegron Er | Mirabegron | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | 12 |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Metaxalone | Metaxalone | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,390.93 · 111 records | Novo Nordisk Inc | ABRYSVO, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, CONTRAVE, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, INSPIRE, JARDIANCE, KYPHON EXPRESS II KYPHOPAK TRAY, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAQEL, Wegovy, ZAVZPRET, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error